Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: EOLS

Evolus, Inc.

Healthcare | Drug Manufacturers - Specialty & Generic

No licensed closing price on file for EOLS. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.51

Evolus, Inc. (NASDAQ: EOLS) is a specialty and generic drug manufacturer. Figures from SEC EDGAR; updated 2026-10-20 03:16 UTC.

What Evolus, Inc. does

The company is a global performance beauty company focused on the cash-pay aesthetic market, where consumers pay directly for medical products delivered by licensed aesthetic practitioners. The company's primary products are Jeuveau, a botulinum toxin type A formulation for frown lines, and Evolysse, a line of injectable hyaluronic acid gels for wrinkles and folds. Jeuveau is currently available in the United States, Canada, certain European markets, and Australia, supported by clinical data from the TRANSPARENCY program.

Summarized from Evolus, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.51

Revenue, margins & earnings

FY2021: net loss $47M on revenue $100M$100MFY2021FY2022: net loss $74M on revenue $149M$149MFY2022FY2023: net loss $62M on revenue $202M$202MFY2023FY2024: net loss $50M on revenue $266M$266MFY2024FY2025: net loss $52M on revenue $297M$297MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-04
  • 2026-09-04See RemarksSale-105,108$950.0K
  • 2026-03-20See RemarksSale-3,119$14.8K
  • 2026-03-20See RemarksSale-13,669$64.9K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Evolus, Inc. do?

The company is a global performance beauty company focused on the cash-pay aesthetic market, where consumers pay directly for medical products delivered by licensed aesthetic practitioners.

When did EOLS last file with the SEC?

Evolus, Inc.'s most recent SEC filing on record is a SCHEDULE 13G filed 2026-08-31. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 03:16 UTC. This page is also available as JSON at /api/data?ticker=EOLS and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for EOLS and 5,000+ tickers.

Create a free account — keep EOLS
For your agent
GET /api/data?ticker=EOLS

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt